Entry
Name
Dapsone (USP); Diaphenylsulfone (JAN); Aczone (TN)
Product
Generic
DAPSONE (ANI Pharmaceuticals) ,
DAPSONE (Alembic Pharmaceuticals) ,
DAPSONE (Amneal Pharmaceuticals LLC) ,
DAPSONE (Amneal Pharmaceuticals NY LLC) ,
DAPSONE (Aphena Pharma Solutions - Tennessee) ,
DAPSONE (AvKARE) ,
DAPSONE (Cosette Pharmaceuticals) ,
DAPSONE (Encube Ethicals Private Limited) ,
DAPSONE (Golden State Medical Supply) ,
DAPSONE (Jacobus Pharmaceutical Company) ,
DAPSONE (Mayne Pharma Commercial LLC) ,
DAPSONE (Mayne Pharma) ,
DAPSONE (Mylan Pharmaceuticals) ,
DAPSONE (NORTHSTAR RX LLC) ,
DAPSONE (NORTHSTAR RX LLC) ,
DAPSONE (Nostrum Laboratories) ,
DAPSONE (Pacific Pharma) ,
DAPSONE (Rising Pharma Holdings) ,
DAPSONE (Taro Pharmaceuticals U.S.A.) ,
DAPSONE (Taro Pharmaceuticals U.S.A.) ,
DAPSONE (Taro Pharmaceuticals U.S.A.) ,
DAPSONE (Torrent Pharmaceuticals Limited) ,
DAPSONE (Trupharma) ,
DAPSONE (Westminster Pharmaceuticals)
Formula
C12H12N2O2S
Exact mass
248.0619
Mol weight
248.3009
Structure
Mol file KCF file DB search
Simcomp
Neighbor
Class
Metabolizing enzyme substrate
DG02855 CYP2E1 substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
Remark
Efficacy
Antibacterial (leprostatic)
Disease
Comment
Diaminodiphenylsulfone derivative
Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency [DS:
H00668 ] are more prone to hemolysis with the use of Dapsone.
Suppression of dermatitis herpetiformis
Target
dihydropteroate synthase [KO:
K00796 ]
Pathway
Metabolism
Enzyme: CYP2E1 [HSA:
1571 ], CYP3A4 [HSA:
1576 ]
Interaction
DDI search
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303 ]
D DERMATOLOGICALS
D10 ANTI-ACNE PREPARATIONS
D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE
D10AX Other anti-acne preparations for topical use
D10AX05 Dapsone
D00592 Dapsone (USP) <JP/US>
J ANTIINFECTIVES FOR SYSTEMIC USE
J04 ANTIMYCOBACTERIALS
J04B DRUGS FOR TREATMENT OF LEPRA
J04BA Drugs for treatment of lepra
J04BA02 Dapsone
D00592 Dapsone (USP) <JP/US>
USP drug classification [BR:br08302 ]
Antimycobacterials
Antimycobacterials, Other
Dapsone
D00592 Dapsone (USP)
Dermatological Agents
Topical Anti-infectives
Antibacterials, dermatological
Dapsone
D00592 Dapsone (USP)
Therapeutic category of drugs in Japan [BR:br08301 ]
2 Agents affecting individual organs
26 Epidermides
269 Miscellaneous
2699 Others
D00592 Dapsone (USP); Diaphenylsulfone (JAN)
6 Agents against pathologic organisms and parasites
62 Chemotherapeutics
623 Leprostatics
6231 Sulfones
D00592 Dapsone (USP); Diaphenylsulfone (JAN)
Drug groups [BR:br08330 ]
Metabolizing enzyme substrate
DG02855 CYP2E1 substrate
D00592 Dapsone
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D00592 Dapsone
Antimicrobials [BR:br08307 ]
Antibacterials
Folic acid biosynthesis inhibitor
Diaminodiphenyl sulfone
D00592 Dapsone (USP) <JP/US>
Drug metabolizing enzymes and transporters [br08309.html ]
Drug metabolizing enzymes
D00592
Pharmacogenomic biomarkers [br08341.html ]
Polymorphisms and mutations affecting drug response
D00592
Prodrugs [br08324.html ]
D00592
BRITE hierarchy
Other DBs
LinkDB
All DBs
KCF data
Show ATOM 17
1 S4a S 21.9800 -14.6136
2 C8y C 23.1922 -15.3246
3 C8y C 20.7736 -15.3187
4 O3c O 20.9776 -13.6228
5 O3c O 22.9708 -13.6228
6 C8x C 24.4045 -14.6195
7 C8x C 23.1922 -16.7234
8 C8x C 19.5614 -14.6136
9 C8x C 20.7736 -16.7175
10 C8x C 25.6050 -15.3187
11 C8x C 24.4045 -17.4168
12 C8x C 18.3433 -15.3187
13 C8x C 19.5614 -17.4168
14 C8y C 25.6167 -16.7234
15 C8y C 18.3433 -16.7175
16 N1a N 26.8174 -17.4285
17 N1a N 17.1369 -17.4168
BOND 18
1 1 2 1
2 1 3 1
3 1 4 2
4 1 5 2
5 2 6 2
6 2 7 1
7 3 8 2
8 3 9 1
9 6 10 1
10 7 11 2
11 8 12 1
12 9 13 2
13 10 14 2
14 12 15 2
15 14 16 1
16 15 17 1
17 11 14 1
18 13 15 1